“Not relevant” responses (NRRs) on the Dermatology Life Quality Index (DLQI) are common among adults with psoriasis and may be associated with underestimation of disease burden. Little is known about “not relevant” responses among adults with atopic dermatitis. We aimed to examine the frequency of NRRs on the DLQI and to determine whether NRRs are associated with underestimation of disease burden among adults with atopic dermatitis.
Adults with atopic dermatitis were identified and evaluated via online survey. We evaluated the frequency of NRRs on the DLQI, stratified by sociodemographic characteristics. To examine the association between NRRs and other measures of disease burden, Patient-Oriented Eczema Measure (POEM), Patient-Oriented SCORAD (PO-SCORAD), and Short-Form (SF)-12 scores were compared between those who responded “not relevant” versus “not at all”.
Among 764 adults with atopic dermatitis, most had mild disease. The median (interquartile range [IQR]) POEM, PO-SCORAD, and DLQI scores were 5 (2–10), 24 (14–34), and 2 (1–6), respectively. Most (55.2%) also had at least one NRR, and 17.9% had 4 or more “not relevant” responses, with differences across several sociodemographic characteristics. There were no substantial differences in SF-12, POEM, and PO-SCORAD scores between those who responded “not relevant” versus “not at all”.
NRRs on the DLQI are common among adults with atopic dermatitis and differ across sociodemographic characteristics, suggesting issues with content validity. There is not a clear association between NRRs and other measures of disease severity among adults with mostly mild atopic dermatitis.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Code availability (software application or custom code)
Available upon request.
Finlay, A. Y., & Khan, G. K. (1994). Dermatology Life Quality Index (DLQI)—A simple practical measure for routine clinical use. Clinical and Experimental Dermatology, 19, 210–216.
Basra, M. K. A., Fenech, R., Gatt, R. M., Salek, M. S., & Finlay, A. Y. (2008). The Dermatology Life Quality Index 1994–2007: A comprehensive review of validation data and clinical results. British Journal of Dermatology, 159, 997–1035.
Vincent, R., Chalmers, J. R., McWilliams, C., Thomas, K. S., Dodd, S., Rogers, N., et al. (2020). Assessing uptake of the Harmonising Outcome Measures for Eczema (HOME) Core outcome set and recommended instruments. British Journal of Dermatology, 183(3), 566–568.
Smith, C. H., Jabbar-Lopez, Z. K., Yiu, Z. Z., Bale, T., Burden, A. D., Coates, L. C., et al. (2017). British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. British Journal of Dermatology, 177, 628–636.
Rencz, F., Gulácsi, L., Péntek, M., Szegedi, A., Remenyik, É., Bata-Csörgő, Z., et al. (2019). DLQI-R scoring improves the discriminatory power of Dermatology Life Quality Index in psoriasis, pemphigus and morphea patients. British Journal of Dermatology, 182(5), 1167–1175.
Rencz, F., Brodszky, V., Gulácsi, L., Péntek, M., Poór, A. K., Holló, P., et al. (2019). Time to revise the DLQI scoring in psoriasis treatment guidelines. Journal of the European Academy of Dermatology and Venereology, 33(7), e267–e269.
Gergely, L. H., Gáspár, K., Brodszky, V., Kinyó, Á., Szegedi, A., Remenyik, É., et al. (2020). Validity of EQ-5D-5L, Skindex-16, DLQI and DLQI-R in patients with hidradenitis suppurativa. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.16642.
Barbieri, J., & Gelfand, J. M. (2018). Evaluation of the Dermatology Life Quality Index scoring modification, the DLQI-R score, in two independent populations. British Journal of Dermatology, 180(4), 939–940.
Gupta, V., Taneja, N., Sati, H. C., Sreenivas, V., & Ramam, M. (2020). Evaluation of “not relevant” responses on the Dermatology Life Quality Index (DLQI) and the DLQI-R scoring modification among Indian patients with vitiligo. British Journal of Dermatology, 184(1), 168–169.
Barbieri, J. S., & Gelfand, J. M. (2019). Influence of “not relevant” responses on the Dermatology Life Quality Index (DLQI) for patients with psoriasis in the United States. JAMA Dermatology, 155, 743–745.
Barbieri, J. S., Shin, D. B., Syed, M. N., Takeshita, J., & Gelfand, J. M. (2020). Evaluation of the frequency of “not relevant” responses on the Dermatology Life Quality Index by sociodemographic characteristics of patients with psoriasis. JAMA Dermatology, 156(4), 446–450.
Rencz, F., Poór, A. K., Péntek, M., Holló, P., Kárpáti, S., Gulácsi, L., et al. (2018). A detailed analysis of “not relevant” responses on the DLQI in psoriasis: Potential biases in treatment decisions. Journal of the European Academy of Dermatology and Venereology, 32, 783–790.
Rencz, F., Gulácsi, L., Péntek, M., Poór, A. K., Sárdy, M., Holló, P., et al. (2018). Proposal of a new scoring formula for the DLQI in psoriasis. British Journal of Dermatology, 179(5), 1102–1108.
Nijsten, T. (2012). Dermatology life quality index: Time to move forward. Journal of Investigative Dermatology, 132, 11–13.
Chiesa Fuxench, Z. C., Block, J., Boguniewicz, M., Boyle, J., Fonacier, L., Gelfand, J. M., et al. (2018). Atopic Dermatitis in America Study: A cross-sectional study examining the prevalence and disease burden of atopic dermatitis in the US adult population. Journal of Investigative Dermatology, 139(3), 583–590.
Williams, H. C., Burney, P. G., Pembroke, A. C., & Hay, R. J. (1996). Validation of the U.K. diagnostic criteria for atopic dermatitis in a population setting. U.K. diagnostic criteria for atopic dermatitis working party. British Journal of Dermatology, 135, 12–7.
Naleway, A. L., Belongia, E. A., Greenlee, R. T., Kieke, B. A., Chen, R. T., & Shay, D. K. (2003). Eczematous skin disease and recall of past diagnoses: Implications for smallpox vaccination. Annals of Internal Medicine, 139, 1–7.
Hongbo, Y., Thomas, C. L., Harrison, M. A., Salek, M. S., & Finlay, A. Y. (2005). Translating the science of quality of life into practice: What do dermatology life quality index scores mean? Journal of Investigative Dermatology, 125, 659–664.
Charman, C. R., Venn, A. J., & Williams, H. C. (2004). The patient-oriented eczema measure: Development and initial validation of a new tool for measuring atopic eczema severity from the patients’ perspective. Archives of Dermatology, 140, 1513–1519.
Spuls, P. I., Gerbens, L. A. A., Simpson, E., Apfelbacher, C. J., Chalmers, J. R., Thomas, K. S., et al. (2017). Patient-Oriented Eczema Measure (POEM), a core instrument to measure symptoms in clinical trials: A Harmonising Outcome Measures for Eczema (HOME) statement. British Journal of Dermatology, 176, 979–84.
Silverberg, J. I., Gelfand, J. M., Margolis, D. J., Fonacier, L., Boguniewicz, M., Schwartz, L. B., et al. (2018). Severity strata for POEM, PO-SCORAD, and DLQI in US adults with atopic dermatitis. Annals of Allergy, Asthma, & Immunology, 121(464–468), e3.
Stalder, J.-F., Barbarot, S., Wollenberg, A., Holm, E. A., De Raeve, L., Seidenari, S., et al. (2011). Patient-Oriented SCORAD (PO-SCORAD): A new self-assessment scale in atopic dermatitis validated in Europe. Allergy, 66, 1114–1121.
Busija, L., Ackerman, I. N., Haas, R., Wallis, J., Nolte, S., Bentley, S., et al. (2020). Adult measures of general health and health-related quality of life. Arthritis Care & Research, 72(Suppl 10), 522–564.
Ware, J., Kosinski, M., & Keller, S. D. (1996). A 12-item Short-Form Health Survey: Construction of scales and preliminary tests of reliability and validity. Medical Care, 34, 220–233.
Jenkinson, C., Layte, R., Jenkinson, D., Lawrence, K., Petersen, S., Paice, C., et al. (1997). A shorter form health survey: Can the SF-12 replicate results from the SF-36 in longitudinal studies? Journal of Public Health and Medicine, 19, 179–186.
Gandek, B., Ware, J. E., Aaronson, N. K., Apolone, G., Bjorner, J. B., Brazier, J. E., et al. (1998). Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: Results from the IQOLA Project. International Quality of Life Assessment. Journal of Clinical Epidemiology, 51, 1171–8.
Hinkle, D., Wiersma, W., & Jurs, S. (2003). Applied statistics for the behavioral sciences (5th ed.). Boston: Houghton Mifflin.
The GfK Group Project Report for the Atopic Dermatitis in America Study. GfK; 2017.
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., et al. (2007). The strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies. Lancet (London, England), 370, 1453–1457.
He, Z., Lu, C., Basra, M. K. A., Ou, A., Yan, Y., & Li, L. (2013). Psychometric properties of the Chinese version of Dermatology Life Quality Index (DLQI) in 851 Chinese patients with psoriasis. Journal of the European Academy of Dermatology and Venereology, 27, 109–115.
Hahn, H. B., Melfi, C. A., Chuang, T. Y., Lewis, C. W., Gonin, R., Hanna, M. P., et al. (2001). Use of the Dermatology Life Quality Index (DLQI) in a midwestern US urban clinic. Journal of the American Academy of Dermatology, 45, 44–48.
Mazzotti, E., Barbaranelli, C., Picardi, A., Abeni, D., & Pasquini, P. (2005). Psychometric properties of the Dermatology Life Quality Index (DLQI) in 900 Italian patients with psoriasis. Acta Dermato-Venereologica, 85, 409–413.
Terwee, C. B., Prinsen, C. A. C., Chiarotto, A., Westerman, M. J., Patrick, D. L., Alonso, J., et al. (2018). COSMIN methodology for evaluating the content validity of patient-reported outcome measures: A Delphi study. Quality of Life Research: An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation, 27, 1159–70.
Langenbruch, A., Radtke, M. A., Gutknecht, M., & Augustin, M. (2018). Does the Dermatology Life Quality Index (DLQI) underestimate the disease-specific burden of psoriasis patients? Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.15226.
Dr. Barbieri is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under award number T32-AR-007465 and receives partial salary support through a Pfizer Fellowship in Dermatology Patient Oriented Research grant to the Trustees of the University of Pennsylvania. Dr. Takeshita is supported by NIAMS K23-AR068433. Dr. Chiesa Fuxench is supported by a Career Development Award through the Dermatology Foundation for work related to atopic dermatitis. Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Conflict of interest
Dr. Takeshita receives a research grant from Pfizer Inc (to the Trustees of the University of Pennsylvania) for work that is unrelated to this study and has received payment for continuing medical education work related to psoriasis that was supported indirectly by Eli Lilly. Dr. Chiesa Fuxench has served as a consultant for the National Eczema Association, Asthma and Allergy Foundation, Sanofi, Pfizer, and AbbVie receiving honoraria, and receives or has received research grants (to the Trustees of the University of Pennsylvania) from Regeneron, Sanofi, Leo, Menlo Therapeutics, Tioga and Vanda pharmaceuticals for clinical trials related to atopic dermatitis; and has received payment for continuing medical education work related to atopic dermatitis that was supported indirectly by Sanofi and Regeneron.
This study was deemed exempt by the University of Pennsylvania Institutional Review Board.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Barbieri, J.S., Chiesa Fuxench, Z.C., Shin, D.B. et al. Frequency and influence of “not relevant” responses on the Dermatology Life Quality Index among adults with atopic dermatitis. Qual Life Res (2021). https://doi.org/10.1007/s11136-021-02770-z
- Atopic dermatitis
- Dermatology Life Quality Index
- Quality of life
- Health-related quality of life
- Not relevant response